Health sciences Company
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, Forum) is one step closer to understanding the full potential of its solution to treat glioblastoma, the most aggressive cancer that begins within the brain. On Wednesday, the Company released further positive results from its scorpion venom-derived peptide research and development program, confirming that its peptides can help block these cancerous cells.
Further details on this study can be found
here.
Since PreveCeutical began screening scorpion venom-derived peptides back in
March 2019, the Company intends to generate
Nature Identical peptide therapeutics intended for therapeutic applications.
FULL DISCLOSURE: PreveCeutical Medical Inc. is a client of Stockhouse Publishing.